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ASOCIACIÓN ENTRE VARIANTES GENÉTICAS
RELACIONADAS CON EL METABOLISMO
LIPÍDICO Y ENERGÉTICO Y LA PÉRDIDA
DE PESO TRAS UNA INTERVENCIÓN
EN ADOLESCENTES CON SOBREPESO
U OBESIDAD
Resumen
Antecedentes: Algunas variantes genéticas relacionadas con
el metabolismo lipídico y energético pueden estar implicadas en
la respuesta a una intervención nutricional además de estar aso-
ciadas con el desarrollo de obesidad y comorbilidades asociadas.
Objetivo: En este sentido, este artículo analiza cuatro poli-
morfismos situados en cuatro genes que han sido previamente
asociados con la obesidad u otras complicaciones asociadas a la
misma, así como su posible papel en la respuesta a una interven-
ción para la pérdida de peso en adolescentes con sobrepeso u
obesidad.
Métodos: La población en estudio está formada por 199 ado-
lescentes con sobrepeso u obesidad (13-16 años) llevando a cabo
una intervención multidisciplinar de 10 semanas para la pérdi-
da de peso: programa EVASYON (www.estudioevasyon.org).
Los adolescentes fueron genotipados para los 4 SNPs y tanto al
comienzo como al final de la intervención se analizaron marca-
dores bioquímicos y se tomaron medidas antropométricas.
Resultados: Rs662799 del gen APOA5 se asoció al inicio con
parámetros antropométricos y bioquímicos, mientras que el
rs9939609 del gen FTO parecía estar asociado con el cambio de
estas variables tras 10 semanas de intervención. Las variantes
rs1800777 del gen CETP y rs670 del gen APOA1 mostraron una
importante asociación con marcadores de adiposidad. Concre-
tamente, un modelo combinado incluyendo los dos polimorfis-
mos logró explicar hasta un 24% del cambio en el IMC-SDS tras
10 semanas de intervención.
Conclusión: Variantes genéticas previamente relacionadas
con el metabolismo lipídico y energético, pueden repercutir no
solamente en valores bioquímicos sino también en la respuesta a
una intervención multidisciplinar para la pérdida de peso en
adolescentes con sobrepeso u obesidad.
(Nutr Hosp. 2014;30:75-83)
DOI:10.3305/nh.2014.30.1.7542
Palabras clave: APOA1. CETP. EVASYON. FTO. APOA5.
Abstract
Background: Some SNPs related to lipid and energy metabo-
lism may be implicated not only in the development of obesity
and associated comorbidities, but also in the weight loss
response after a nutritional intervention.
Objective: In this context, the present study analyzed four
SNPs located within four genes known to be associated with
obesity and other obesity-related complications, and their puta-
tive role in a weight-loss intervention in overweight/obese
adolescents.
Methods: The study population consisted of 199
overweight/obese adolescents (13-16 yr old) undergoing 10
weeks of a weight loss multidisciplinary intervention: the
EVASYON programme (www.estudioevasyon.org). Adoles-
cents were genotyped for 4 SNPs, and anthropometric measure-
ments and biochemical markers were analyzed at the beginning
and after the intervention.
Results: Interestingly, APOA5(rs662799) was associated
with the baseline anthropometric and biochemical outcomes,
whereas FTO (rs9939609) seemed to be related with the change
of these values after the 10-week intervention. The other two
SNPs, located in the CETP (rs1800777) and the APOA1 (rs670)
genes, showed important relationships with adiposity markers.
Specifically, a combined model including both SNPs turned up
to explain up to 24% of BMI-SDS change after 10 weeks of the
multidisciplinary intervention, which may contribute to under -
stand the weight loss response.
Conclusion: Common variants in genes related to lipid and
energy metabolism may influence not only biochemical
outcomes but also weight loss response after a multidisciplinary
intervention carried out in obese/overweight adolescents..
(Nutr Hosp. 2014;30:75-83)
DOI:10.3305/nh.2014.30.1.7542
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Introduction
Overweight and obesity during childhood and
adolescence has became a growing public health
problem throughout the world1-2 to the extent that,
according to the European Association for the Study of
Obesity (EASO), about 16-22% of European adoles-
cents between 14 and 17 years old are overweight or
obese, with an annual increase of the prevalence of
around 2% in the 1990s and 2000s3. These rates in
childhood and adolescent obesity appear to be associa -
ted with important comorbidities in adulthood, such as
type 2 diabetes, coronary artery disease or atheroscle-
rosis, accompanied by elevated costs for public health
systems4,5. Besides, the imbalance between an
increased energy intake and a decreased energy expen-
diture due to inadequate dietary habits and physical
activity patterns, genetic factors, as well as gene x gene
and gene x environment interactions, may be also
involved in obesity aetiology accounting for 40-70% of
obesity phenotypes6.
Concerning the genetic basis of obesity, several
SNPs located in different genes have been found to be
associated with adiposity, dietary patterns or weight
loss7,8. In this context, several studies have shown
significant relationships between adiposity, dyslipi-
demia, hypertension, diabetes or an increased cardio-
vascular risk and individual SNPs9-18, including
APOA1, APOA5, FTO and CETP, which are genes
involved in the regulation of plasma lipid levels. Four
SNPs that have been previously found to influence
plasma lipid levels and cardiovascular disease are
rs670 (APOA1), rs662799 (APOA5), rs1800777
(CETP) and rs9939609 (FTO)19-23. Thus, APOA1 is a
gene that encodes for Apolipoprotein A-1, the major
protein component of HDL-cholesterol24. APOA5
encodes for Apolipoprotein A-V, a component of
several lipoprotein factors as VLDL or HDL and an
important determinant of plasma triglyceride levels25.
As for FTO gene, it has been widely associated with
obesity26-28. Finally, CETP encodes for the plasma lipid
transfer protein, a plasma protein that facilitates the
transport of cholesterol esters and triglycerides
between the lipoproteins29. However, the effects of the
four SNPs after a lifestyle intervention for weight loss
are in most cases still scarce. Therefore, our purpose
was to evaluate the effect of these SNPs located in
FTO, APOA5, APOA1 and CETP genes, which have
been previously associated with obesity, dyslipidemia
and other obesity-related pathologies, in the metabolic
response after a weight-loss intervention in over-
weight/obese adolescents.
Subjects and methods
The trial recruited 199 overweight or obese adoles-
cents (39% males) undergoing a 10 week intensive
lifestyle intervention, the EVASYON study (www.
estudioevasyon.org), which is a lifestyle and nutri-
tional educational weight loss program supported by a
multidisciplinary team of nutritionists, physiothera-
pists, psychologists and paediatricians. Data from
these adolescents were collected at the beginning and
after 10 weeks of treatment and participants were
recruited from five Spanish cities (Granada, Madrid,
Pamplona, Santander and Zaragoza). The study
included only 12 to 16 years old overweight or obese
adolescents, according to Cole s criteria30, which have
been raised in Spain and without diagnosed disease
associated with obesity or pharmacological treatment.
Written consent to participate was requested from
both parents and adolescents. The study protocols were
performed in accordance with the ethical standards laid
down in the 1961 Declaration of Helsinki (as revised in
South Korea in 2008), following the European
Economic Community (EEC) Good Clinical Practice
guidelines (document 111/3976/88 of July 1990) and
current Spanish laws, which regulates clinical research
in humans (Royal Decree 561/1993 regarding clinical
trials). The study was approved by the five local ethics
committees.
Multidisciplinary intervention
According to food intake questionnaires, a persona -
lized balanced diet (30% of energy as fat, 15% as
proteins and 55% as carbohydrates) and a physical
activity programme was handed in to each adolescent.
During the 10 week intensive program period, the
adolescents attended weekly group sessions where
they received nutritional and physical advice, as well
as psychological support. The description of the
complete EVASYON study design has been previ-
ously published elsewhere31.
Physical Activity, Energy Intake, Metabolic
and Anthropometric Data
All the adolescents were asked to fill in a series of
validated questionnaires in order to determine their
physical activity level and estimate their basal metabo-
lism rates31,32. A semi-quantitative food-frequency
questionnaire, previously validated in Spain33, and
containing 132 food items, as well as a 72-hour recall
was filled in at the beginning of the follow-up. Weight
and height were measured with an electronic scale
(Type SECA 861, SECA, Birmingham, UK) and a teles -
copic height measuring instrument (Type SECA 225,
SECA, Birmingham, UK) respectively. BMI was
calculated as weight (in kg)/height2 (in m2). Then, indi-
vidual BMI values were converted into standard devia-
tion scores (SDS) using age and specific cut-points
according to the Spanish children and adolescent
growth references34. Skinfolds were measured with a
skinfold calliper (Caliper Holtain; Holtain Ltd.,
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Walles, UK) and waist and hip circumferences with a
flexible non-stretchable measuring tape (Type SECA
200, SECA, Birmingham, UK). Pubertal develop-
mental was determined according to Tanner stage35.
Blood pressure was obtained using the left arm after the
adolescent had rested quietly for 15 minutes using a
blood pressure monitor Mod. OMRON M6 (OMROM
Health Care Co., Kyoto, Japan) by following validated
procedures.
Genotyping
Venous blood samples were collected at the begin-
ning of the study. DNA was extracted from the buffy
coat fraction using a commercial kit (Master PureTM;
Epicentre, Madison, WI, USA) and its quality and
quantity were determined with a NanoDrop ND-1000
spectrometer (NanoDrop Technologies, Wilmington,
Delaware, USA). All the subjects were genotyped for 4
SNPs located within APOA1, APOA5, FTO and CETP
genes (rs670, rs662799, rs1800777 and rs9939609,
respectively) by using the N+S nutrigenetic test of
CINFA (Olloki, Spain). Briefly, targeted regions of
genomic DNA were amplified in a multiplex PCR
reaction using biotinylated dCTP by using an Applied
Biosystems gold plated 96-well Geneamp® PCR
System 9700 (Applied Biosystems, Foster City, CA,
USA). The PCR products were then hybridized onto
oligonucleotide probes attached to microspheres and
labeled with streptavidin-conjugated phycoerythrin
(Luminex xMAP® Technology). These beads were
analyzed by flow cytometry with the Luminex®
100/200TM System (Luminex Corporation, Austin,
TX, USA) by following the usual protocol36. The pre -
sence of specific polymorphisms in the sample mate-
rial was determined by correlation of the fluorescence
signal intrinsic to each microsphere with the presence
or absence of a corresponding phycoerythrin signal.
Replicate quality control samples were included in
every genotyping plate with more than 99% of concor-
dance.
Statistical analysis
Statistical analyses were performed using the Statis-
tical Package for the Social Sciences (SPSS) software
15.0 (SPSS INC., Chicago, IL). A χ2 test was used to
evaluate the Hardy-Weinberg equilibrium. The
Kolmogorov-Smirnov test was used to determine
varia ble distribution. 
The differences in anthropometric, biochemical and
energy intake variables between the SNP genotypes
were tested with analysis of the covariance
(ANCOVA) adjusted for confounders such as age, sex
or baseline BMI-SDS (for normally distributed varia -
bles), or the Mann Whitney U test. Multivariate regres-
sion models were fitted to assess the association
between the genotypes and weight loss after adjusting
for confounder factors. The level of probability was set
at p < 0.05 as statistically significant.
Results
The present study analyzed four SNPs located in
APOA1, APOA5, FTO and CETP genes, previously
associated with obesity, diabetes, dyslipidemia and
other obesity-related pathologies. Allele frequencies of
the four studied SNPs were within expected ranges for
Caucasian populations and the Hardy Weinberg equi-
librium was fulfilled in this population.
Anthropometric, biochemical and physical activity
markers and determinants as well as dietary patterns for
overweight/obese adolescents at baseline and after 10
weeks of the EVASYON programme, are shown (table
I). Adiposity markers, such as weight, BMI-SDS, fat
mass and waist circumference, were significantly
reduced. In a similar way, the metabolic profile of the
adolescents was improved after the intervention. There
was a significant decrease in leptin, insulin, total choles-
terol, triglycerides and C-reactive protein among other
parameters. In regard to physical activity, obese adoles-
cents not only decreased their sedentary behaviour but
also improved their physical skills. Finally, after 10
weeks of intervention, the adolescents showed a signifi-
cant improvement of dietary patterns decreasing total
energy, total fat and SFA intake (table I).
Concerning plasma lipid levels, the rs662799 SNP
of the APOA5 gene was associated with higher levels
of HDL-cholesterol at the beginning of the intervention
(B = 7.22; TEM = 2.80; p = 0.011) but no differences
were found after the intervention. Meanwhile,
rs9939609 SNP of the FTO gene was associated with a
higher decrease of HDL-cholesterol after the interven-
tion (B = -4.00; TEM = 1.39; p = 0.005), as well as with
a higher decrease of apolipoprotein A1 after 10 weeks
of the EVASYON intervention (B = -7.88; TEM =
3.10; p = 0.013). On the other hand, rs670 SNP of the
APOA1 gene showed an association with apolipopro-
tein B levels; G allele carriers presented higher base-
line apolipoprotein B plasma concentrations and, after
10 weeks of a multidisciplinary intervention, they
achieved a greater decrease of the circulating levels of
this apolipoprotein.
The four SNPs studied (rs670 of APOA1 gene,
rs662799 of APOA5 gene, rs9939609 of FTO gene and
rs1800777 of CETP gene), showed a strong association
with adiposity indicators, both at the beginning and
after 10 weeks of the EVASYON treatment (table II).
In particular, SNPs in APOA1 and CETP genes
evidenced a significant association with weight and
BMI-SDS loss after the intervention (Figure 1A and
1B). Regression analyses studying these effects are
showed (table III). Concerning BMI-SDS reduction,
both SNPs showed a significant effect (figs. 2A and
2B). Particularly, rs670 of APOA1 gene seemed to
Common variants in genes related to lipid
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explain more than a 20% of this BMI-SDS change after
adjusting for age and sex. Moreover, the analysis of the
combined effect of both SNPs turned out to explain
more than a 24% of BMI-SDS loss after the interven-
tion, with a decrease of 0.24 points of BMI-SDS for
each minor allele present in the genotype. Similar
results were obtained for weight loss. A combined
regression model of APOA1 and CETP was able to
explain more than a 14% of weight loss after the inter-
vention. For each minor allele present in the adolescent
genotypes, they showed a decrease of -1.4 kg in body
weight. 
Discussion
In this study, we analyzed the contribution of four
obesity-related SNPs located in the APOA1, APOA5,
FTO and CETP genes to adiposity markers in a Spanish
population of overweight and obese adolescents under-
going a multidisciplinary intervention programme for
weight loss (EVASYON). 
After three months of treatment, the adolescents
achieved a significant decrease in adiposity, as well as
an improvement in their physical skills and in their
metabolic profile. Thus, a significant decrease in
leptin, insulin, glucose and C-reactive protein levels,
among other parameters, confirmed the effectiveness
of the EVASYON project as an overweight/obese
adolescent weight loss programme. Similar results
were found in a pilot study of the EVASYON
programme37.
ApoA1 and ApoA2 are the major protein
constituents of HDL-cholesterol. Concerning rs670
SNP of the APOA1 gene, a strong association with
weight and BMI-SDS loss after the 10-weeks interven-
Table I
Anthropometric, biochemical, physical activity and dietary data concerning the participant adolescents (n = 199)
at the beginning and after 10 weeks of intervention
At the beginning After 10 weeks
Mean TEM Mean TEM p
Gender (% boys) 39.2
Age (yr) 14.5 0.08 80.2 1.1 < 0.001
Weight 83.8 1.2 80.2 1.1 < 0.001
BMI-SDS 4.5 0.2 3.8 0.1 < 0.001
Waist circunference (cm) 103.5 0.8 101.6 0.8 < 0.001
Hip circunference (cm) 90.8 2.1 88.1 2 < 0.001
Waist/Hip ratio 1.26 0.03 1.27 0.03 0.08
Waist/Height ratio 0.63 0 0.61 0 < 0.001
SBP (mm Hg) 111 1.5 106.2 1.5 <0.001
DBP (mm Hg) 74.4 0.8 70.2 0.8 < 0.001
Fat mass (kg) 37.3 0.9 32.8 0.8 <0.001
Fat mass (%) 43.7 0.6 40.1 0.5 <0.001
Σ 2 Skinfolds 57.5 0.9 51.7 0.9 < 0.001
Σ 4 Skinfolds 108.5 1.6 99.2 1.6 < 0.001
Σ 7 Skinfolds 179.7 2.2 165.2 2.4 < 0.001
Leptin (pg/ml) 5,158.6 532.3 2,999.9 304.8 < 0.001
Insulin (microU/ml) 18.6 1.9 14.2 1.1 0.005
PYY (pg/ml) 66.4 4.5 63.8 4.8 0.57
Adiponectin (pg/ml) 5,445.8 724.2 5,535.5 722.1 0.702
Glucose (mg/dL) 84.3 0.7 81.5 0.8 < 0.001
Total cholesterol (mg/dL) 155.7 2.5 143 2.5 <0.001
Tryglicerides (mg/dL) 92.9 4.1 83.3 3.9 0.002
HDL-cholesterol (mg/dL) 46.4 1 44.5 1 0.006
LDL-cholesterol (mg/dL) 90.1 2.2 82 2.2 0.009
CRP (mg/dL) 2.8 0.3 2 0.2 0.006
Sedentary activity (min/week) 543.8 6.4 521.8 6.8 0.002
Physical activity (counts) 377 13.9 408.6 13.2 0.011
Total energy (kcal) 2,188.8 68.1 1,685 56.8 < 0.001
Protein (gr) 100.9 3.6 94.7 3.3 0.047
Carbohydrates (g) 208.8 7.5 172.4 6.6 < 0.001
Lipids (g) 104.9 3.7 68 2.8 <0.001
SFA (g) 34 1.2 22.3 0.9 < 0.001
MUFA (g) 44.2 1.8 28.8 1.4 < 0.001
PUFA (g) 17 0.8 10 0.5 < 0.001
SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; PYY: Peptide YY; SFA: Saturated Fatty Acids; MUFA: Monounsaturated Fatty
Acids; PUFA: Polyunsaturated Fatty Acids.
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tion was found, but there were no significant associa-
tions with plasma lipid profile before or after the inter-
vention. In this sense, a study carried out by Xiao et al.38
did not found a relationship between the SNP and
plasma HDL-cholesterol levels or CVD in a population
of controls and patients with proven CVD. On the other
hand, other studies have reported an interaction
between the SNP and dietary nutrients on plasma lipid
levels and the metabolic syndrome. Thus, Phillips et
al., found in a study of metabolic syndrome cases and
controls that APOA1 rs670 may influence metabolic
syndrome, with G allele homozygotes showing an
increased risk of MetS apparently explained by their
increased abdominal obesity and impaired insulin
sensitivity. Moreover, this association could be modu-
lated by sex and dietary fat composition15. In a similar
way, a recent study carried out by Rudkowska et al.39
showed that the rs670 SNP of the APOA1 gene inter-
Common variants in genes related to lipid
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Table II
Anthropometric data according to the SNPs rs670 (APOA1 gener) and rs1800777 (CETP gene).
n = 199 obese/overweight adolescents
APOA1 rs670 CETP rs1800777
XX (n = 102) XY/YY (n = 76) p XX (n = 172) XY/YY (n = 6) p
Weight (kg) -2.9 ± 0.3 -4.5 ± 0.3 < 0.001 -3.4 ± 0.2 -8.0 ± 2.1 < 0.001
BMI-SDS -0.57 ± 0.04 -0.82 ± 0.05 < 0.001 -0.66 ± 0.03 -1.30 ± 0.22 0.001
Weight circumference (cm) -1.0 ± 0.6 -3.0 ± 0.5 0.017 -1.7 ± 0.4 -5.9 ± 1.0 0.067
Waist/hip ratio 0.02 ± 0.01 0.001 ± 0.01 0.154 0.01 ± 0.01 -0.02 ± 0.01 0.279
Waist/height ratio -0.008 ± 0.003 -0.020 ± 0.003 0.022 -0.013 ± 0.002 -0.040 ± 0.004 0.055
Body fat (Σ 7 Skinfolds) -12.0 ± 1.7 -17.4 ± 2.1 0.044 -14.2 ± 1.4 -22.6 ± 7.5 0.227
Fig. 1.—Correlations between the rs670 SNP of the APOA1 gene and the rs1800777 SNP of the CETP gene and IMC-SDS (A) and weight
(B) loss.
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acted with dietary saturated fat on total cholesterol
levels and with dietary total and saturated fat on LDL-
cholesterol levels. 
As for rs662799 SNP of APOA5 gene, it has been
largely associated with the plasma lipid profile40-42. In
this study, this SNP has been identified as a significant
predictor for plasma HDL-cholesterol concentration,
with C allele carriers showing significantly higher
HDL-cholesterol levels. However, these results did not
in agree with works conducted in East Asian popula-
tions41,43. With regards to HDL-cholesterol levels after a
weight loss intervention, data from literature is scarce.
There are some studies analyzing the effect of the SNP
on HDL-cholesterol plasma levels after fenofibrate
therapy. Lai et al.44 found that, after drug intervention,
both carriers and non-carriers of the rs662799 SNP
showed no significant differences in HDL-cholesterol
plasma levels and similar results were described by
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Table III
Regression analyses showing the effect of two SNPs (both individually and combined): rs670 of APOA1 and gene rs 1800777
of CETP gene, on weight and IMC-SDS loss after the intervention. n = 199 obese/overweight adolescents
IMC-SDS loss Weight loss
SNP Gene R2 B TEM p R2 B TEM p
rs670 APOA1 0.213 -0.234 0.05 6.03 × 10-6 0.116 -1.287 0.323 9.8 × 10-5
rs1800777 CETP 0.174 -0.618 0.174 4.8 × 10-4 0.112 -4.426 1.143 1.5 × 10-4
APOA1+CETP 0.241 -0.244 0.045 2.3 × 10-7 0.147 -1.411 0.294 3.3 × 10-6
B: effect for each minor allele present in the genotype. Linear regression analysis adjusted by age and sex.
Fig. 1.—BMI-SDS change
depending on rs670 SNP of
APOA1 (A) and rs1800777
SNP of CETP (B) genotypes.
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Feitosa et al. shortly after45. However, to our know -
ledge, no studies concerning HDL-cholesterol levels
depending on this SNP have been previously
conducted after a multidisciplinary weight loss inter-
vention.
The CETP gene codifies for the cholesteryl ester
transfer protein, which facilitates the transport of
cholesteryl esters and triglycerides between the
lipoproteins and, therefore, participates in plasma lipid
level regulation22. Specifically, the rs1800777 SNP of
the CETP gene is located within the lipid-binding
region and may result in the loss of positive charge,
altering binding of CETP to cholesteryl esters. Results
concerning the analysis of this SNP are scarce. A study
carried out in 2008 by Lu et al. found that, compared
with the ancestral allele the rs1800777 SNP of the
CETP gene was associated with lower plasma HDL-
cholesterol levels46. A meta-analysis also corroborated
that a dominant model of the rs1800777 SNP was
accompanied by lower levels of plasma HDL-choles-
terol22. Our results evidenced that carriers of the
rs1800777 of CETP gene showed a strong association
with adiposity indexes, both at the beginning and after
10 weeks of the EVASYON treatment, especially with
weight and BMI-SDS loss after the intervention.
However, to our knowledge, no studies analyzing the
effects of this SNP after an intervention have been
carried out to date.
Concerning the FTO gene, the rs9939609 SNP has
been widely associated with obesity and cardiovas-
cular disease risk47,48, especially during childhood49-51. It
has been demonstrated that this SNP also influences
weight loss after a weight loss intervention, both in
adults and children or adolescents52. With regards to the
putative impact of rs9939609 on plasma lipid levels,
our study did not shown baseline differences between
the carriers and the non-carriers. On the other hand,
after the 10-week intervention, A allele carriers of the
SNP underwent a significant decrease of HDL-choles-
terol whereas adolescents with a TT genotype
presented a slightly increase in this plasma biomarker.
A study carried out by Freathy et al. found that each
copy of the FTO rs9939609 A allele was associated
with lower baseline HDL cholesterol levels53. So far,
there are no evidences in the literature on the impact
that a weight loss intervention may have on HDL
plasma cholesterol, in spite of the relationship between
FTO gene and lipid metabolism. Most of the studies
carried out after an intervention did not found a direct
effect of rs9939609 SNP on plasma lipid levels54,55. 
One of this study’s strength is the analysis of a popu-
lation of adolescents. This ensures the absence of
obesity-associated comorbidities or pharmacological
treatments that could mask the results. Moreover,
obesity treatment during adolescence should be a
priority subject of study, since improvements in
obesity at this stage have been demonstrated to lead to
maintained changes during adulthood that could
decrease the risk of developing obesity-related comor-
bidities, such as metabolic syndrome56, hypertension57
or even some types of cancer58. 
In conclusion, in this study two SNPs in the APOA5
(rs662799) and FTO (rs9939609) genes were associa -
ted with HDL-cholesterol plasma levels at baseline and
after the intervention, respectively. Moreover, two
SNPs in the CETP (rs1800777) and the APOA1 (rs670)
genes showed important effects on body weight and
adiposity. Specifically, a combined model including
both SNPs turned up to explain up to 24% of BMI-SDS
change after 10 weeks of the multidisciplinary
EVASYON intervention.
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